Peter DeMuth's most recent trade in Elicio Therapeutics Inc. was a trade of 44,400 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Elicio Therapeutics Inc. | Peter DeMuth | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 44,400 | 44,400 | - | - | Stock Option (Right to Buy) | |
| Elicio Therapeutics Inc. | Peter DeMuth | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.41 per share. | 16 Dec 2024 | 381 | 381 | - | 4.4 | 1,680 | Common Stock |
| Elicio Therapeutics Inc. | Peter DeMuth | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 381 | 0 | - | - | Stock Option (Right to Buy) | |
| Elicio Therapeutics Inc. | Peter DeMuth | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 29,800 | 29,800 | - | - | Stock Option (Right to Buy) | |
| Elicio Therapeutics Inc. | DeMuth Peter | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 29,800 | 29,800 | - | - | Stock Option (right to buy) | |
| Elicio Therapeutics Inc. | Peter DeMuth | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 342 | 342 | - | - | Stock Option (right to buy) |